<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00894049</url>
  </required_header>
  <id_info>
    <org_study_id>ITAC02-01</org_study_id>
    <nct_id>NCT00894049</nct_id>
  </id_info>
  <brief_title>A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation</brief_title>
  <acronym>ITAC02-01</acronym>
  <official_title>A Multicenter Prospective Randomized Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective comparison between 2 popular regimens based on reduced intensity
      or non-myeloablative approaches to define the optimal myeloablative and/or
      immu-nonsuppressive association for reduced intensity conditionings (RIC).

      Flu-Bu-ATG (Study A) associated Fludarabine (30mg/m²/5 days), Oral Busulfan (8 mg/kg over 2
      days) and Thymoglobuline (2.5 mg/m²/1day).

      Flu-TBI (Study B) consisted of Fludarabine (25mg/m²/ 3 days) and 2 Gy total body irradiation
      (TBI).

      A randomization of 2 phase study according to the methodology developed by Liu et al (Liu,
      1993 and 2001) for the evaluation of multiple innovative approaches.

      Primary endpoint is one year overall survival (OS). Stopping rules included excessive
      engraftment failure and trans-plant related mortality ratio. Data are yearly reviewed by an
      independent safety review board (ISRB).

      Inclusion criteria are patients presenting a hematological malignancy, eligible for non
      myeloablative allo stem cell transplantation (SCT), aged between 18 and 65, with a suitable
      HLA identical sibling. All patients and donors are included after giving written informed
      consent.

      Protocol was submitted and accepted by the ethical committee and the AFFSSAPS cellular
      therapies committee (national agency).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>one year overall survival (OS)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Allograft</condition>
  <condition>Allogeneic Cell Transplantaion</condition>
  <condition>Hematological Malignancy</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Flu-Bu-ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine (30mg/m²/5 days) Oral Busulfan (8 mg/kg over 2 days) Thymoglobuline (2.5 mg/m²/1day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluda-TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine (25mg/m²/ 3 days) 2 Gy TBI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reduced intensity conditionings</intervention_name>
    <description>comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)</description>
    <arm_group_label>Flu-Bu-ATG</arm_group_label>
    <arm_group_label>Fluda-TBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hematological malignancy or solid tumor,

          -  eligible for non myeloablative allogenic transplantation,

          -  aged between 18 and 65,

          -  with a suitable HLA identical sibling

        Exclusion Criteria:

          -  contra-indication to allogenic transplantation

          -  pregnant women or breast feeding

          -  active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier BLAISE, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Bordeaux Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutpaolicalmettes.fr/</url>
    <description>official site of the sponsor</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>December 31, 2013</last_update_submitted>
  <last_update_submitted_qc>December 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

